Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Net loss, excluding special items, was $0.04 per share in the November quarter, compared to a loss of $0.05 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 8% year-over-year to $72.8 million in the second quarter. The company continues to expect fiscal 2025 sales in the range of $282 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “We are very excited about our strong performance during the second quarter, and in particular the continued strength of our Med Tech segment,
which grew 25% over the prior year.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from Kroger’s (KR) Q1 2025 earnings report
The Kroger Co. (NYSE: KR) recently reported mixed results for the first quarter of fiscal 2025, with earnings beating estimates and sales missing. The grocery giant’s stock rose following the
What to expect when McCormick & Company (MKC) reports Q2 2025 earnings results
Shares of McCormick & Company, Incorporated (NYSE: MKC) gained over 1% on Monday. The stock has dropped 7% over the past three months. The condiments maker is slated to report its second
Earnings Preview: Paychex (PAYX) looks set to end FY25 on a strong note
Paychex Inc. (NASDAQ: PAYX) has benefited from the stable labor market and resilient customers, despite inflationary pressures and the challenging economic environment. The company is leveraging its strong fundamentals and
